GlassScriptPhysician profile
Luke A Eichorn
NPI 1629852868
$1,634.55
in general payments reported to CMS, 2019-2025
21 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $597 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $283.96 | 2024-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $265.98 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $244.19 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $133.27 | 2024-2025 | |
| Glaxosmithkline, LLC. | $105.46 | 2024-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $91.56 | 2024-2025 | Auvelity, Sunosi |
| Merck Sharp & Dohme LLC | $86.80 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Exact Sciences Corporation | $63.14 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $62.49 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $49.52 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $34.39 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.18 | 2024-2025 | Jardiance, Synjardy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.94 | 2025 | Caplyta |
| Lundbeck LLC | $20.77 | 2025 | Rexulti |
| Pacira Pharmaceuticals Incorporated | $20.64 | 2024 | Zilretta, Exparel, Iovera |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $20.19 | 2025 | Omnipod |
| Viatris Specialty LLC | $18.59 | 2025 | Yupelri |
| Collegium Pharmaceutical, INC. | $18.04 | 2025 | Jornay Pm |
| Bayer Healthcare Pharmaceuticals INC. | $17.44 | 2025 | |
| Mylan Specialty L.P. | $17.09 | 2024 | Yupelri |
| Phadia US INC. | $16.91 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Eichorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.